TRAF1 Blocking PeptideProduct information
|100 µg||-||Unavailable in your region|
Product Pathways - Apoptosis
TRAF1 Blocking Peptide #1066
|1066S||100 µg||---||In Stock||---|
|1066||carrier free and custom formulation / quantity||email request|
This product is assembled upon order. Please allow up to three weeks for your product to be processed.
This peptide is used to block TRAF1 (45D3) Rabbit mAb #4715 reactivity in dot blot protocols.
The quality of the peptide was evaluated by reversed-phase HPLC and by mass spectrometry. The peptide blocks TRAF1 (45D3) Rabbit mAb #4715 signal in dot blot.
Directions For Use
Use as a blocking reagent to evaluate the specificity of antibody reactivity in dot blot protocols.
TRAFs (TNF receptor-associated factors) are a family of multifunctional adaptor proteins that bind to surface receptors and recruit additional proteins to form multiprotein signaling complexes capable of promoting cellular responses (1-3). Members of the TRAF family share a common carboxy-terminal "TRAF domain", which mediates interactions with associated proteins; many also contain amino-terminal Zinc/RING finger motifs. The first TRAFs identified, TRAF1 and TRAF2, were found by virtue of their interactions with the cytoplasmic domain of TNF-receptor 2 (TNFRII) (4). The six known TRAFs (TRAF1-6) act as adaptor proteins for a wide range of cell surface receptors and participate in the regulation of cell survival, proliferation, differentiation, and stress responses.
- Arch, R.H. et al. (1998) Genes Dev. 12, 2821-30.
- Chung, J. Y. et al. (2002) J. Cell Sci. 115, 679-88.
- Bradley, J.R. and Pober, J.S. (2001) Oncogene 20, 6482-91.
- Rothe, M. et al. (1994) Cell 78, 681-92.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.